Metastatic Lung Cancer – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Metastatic Lung Cancer – Drugs In Development, 2023’, provides an overview of the Metastatic Lung Cancer pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Metastatic Lung Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Lung Cancer and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Metastatic Lung Cancer
- The report reviews pipeline therapeutics for Metastatic Lung Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Metastatic Lung Cancer therapeutics and enlists all their major and minor projects
- The report assesses Metastatic Lung Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Metastatic Lung Cancer
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Metastatic Lung Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metastatic Lung Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
ABM Therapeutics IncAccurius Therapeutics Inc
AntiCancer Inc
Arjuna Therapeutics
Arrogene Inc
Ascentawits Pharmaceuticals Ltd
AstraZeneca Plc
Beijing FuKangren Bio-pharm Tech Co Ltd
Bristol-Myers Squibb Co
BrYet US Inc
Cancer Targeting Systems Inc
CiMaas BV
Compass Therapeutics Inc
Convalife
CTx Operations Inc
DeoBioSciences Inc
Enfuego Therapeutics Inc
For-Robin Inc
Genemedicine Ltd
Harry Perkins Institute of Medical Research
Hiroshima University
Hokkaido University
Huabo Biopharm (Shanghai) Co Ltd
I-Mab
Immupharma Plc
Institute of Cancer Research
Isarna Therapeutics GmbH
Kadmon Holdings Inc
Kintara Therapeutics Inc
Kintor Pharmaceutical Ltd
LeadArtis SL
MetaStat Inc
Moleculin Biotech Inc
National Cancer Institute US
Nob Hill Therapeutics Inc
Park of Active Molecules
PIN Pharma Inc
Polyplus-Transfection SA
Portage Biotech Inc
Princeton University
Provectus Biopharmaceuticals Inc
QSAM Therapeutics Inc
Replimune Ltd
Roquefort Therapeutics Plc
SL Bigen Co Ltd
SynDevRx Inc
University of California Riverside
University of Strathclyde
Vaxil Bio Therapeutics Ltd
ViruCure Therapeutics Ltd